相关实验视频

Updated: Jun 23, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

用康齐祖马布向组织因子通路抑制剂,以改善格兰兹曼血栓塞病患者的血液静止:一个体外研究

Jade Dubut¹, Valérie Goin², Cloé Derray³

¹Department of Haematology, University Hospital of Bordeaux, Pessac, France; Institut National de la Santé et de la Recherche Médicale U1034, Biology of Cardiovascular Disease, Pessac, France.

Journal of thrombosis and haemostasis : JTH

|June 16, 2024

概括

新型抗体康齐祖马布 (Concizumab) 通过增强血栓生成和凝块稳定性,显著改善了格兰兹曼血栓硬化 (GT) 患者的血液凝结. 这表明治疗这种遗传性出血障碍的潜力.

科学领域:

血液学血液学血液学
血液静止和血栓形成
药理学药理学是指药理学的学科.

背景情况:

格兰兹曼血栓塞 (GT) 是一种遗传性出血障碍,由于血小板α_IIbβ₃整合蛋白的缺陷.
康齐祖马布是一种单克隆抗体向组织因子通路抑制剂,已知可降低其抗凝活性.

研究的目的:

为了研究康齐祖马布在改善格兰兹曼血栓塞的血液静止的体外疗效.
评估康齐祖马布对血栓生成,血块形成和GT患者血液稳定性的影响.

主要方法:

在GT患者的全血和富血小板血中,使用血栓生成试验,旋转血栓形成显微镜 (ROTEM) 和流室试验评估了康齐祖马布的作用.
与洗净血小板 (WPs) 和重组激活因子VII (rFVIIa) 进行比较.

主要成果:

康齐祖马布显著改善了GT患者的血栓生成概况,并减少了GT患者的凝血时间.
在流量测试中,康齐祖马布在GT血液中促进了血栓形成,而此前没有这种情况.
康齐祖马布还增强了凝块的稳定性,降低了对纤维素分解的敏感性.

结论:

康齐祖马布在实验室中显示出对格兰兹曼血栓硬化症具有显著的促凝效应.
这些发现支持康齐祖马布在GT患者皮下预防的潜力.

关键词:

格兰兹曼的血栓硬化症.被激活的复合因子VII.抗α (IIb) 抗β (III) 异抗体.康西祖马布 (Conscizumab) 是一种治疗方法.血小板输血输血血小板输血产生血栓的发生.组织因子通路抑制剂

更多相关视频

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...